Search Results for "Costs%20of%20Care"
Research
01/18/2022
Medicare Part B Premium Dynamics Explained
The Drug Pricing Lab commissioned Milliman to prepare a report exploring the impact of changes in Medicare Part B program costs on beneficiaries’ premiums and Social Security payments. This report focuses on the 2022 Part B premium for beneficiaries with various income levels to illustrate the payment dynamics and discusses the implications for related programs.
Impact Story
09/01/2021
Savings from drug waste funds a $1.2 trillion infrastructure bill
Research
08/13/2021
What A Waste! The National Academy Of Medicine’s Report On Oversized Vials Of Expensive Drugs
Why Congress should not follow the National Academy of Science, Engineering, and Medicine’s recommendation to remove the JW modifier.
Research
04/09/2021
Trump's Drug-Pricing Ideas Would Cost Taxpayers a Bundle
Meanwhile, pharmaceutical companies would stand to make a lot more money.
Person
03/16/2021
Niti Trivedi, MPH
Research Data Analyst, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center
Research
03/15/2021
Modeling P-quad
The Drug Pricing Lab engaged Milliman to conduct an independent analysis of the Production Plus Profit Pricing (P-quad) policy proposal. The Milliman analysis estimates the projected spending on U.S. biologic and biosimilar drugs under a referent scenario where there is no biosimilar entry or competition, the existing ‘status quo’ scenario under the current biosimilar environment, and the Drug Pricing Lab’s P-quad policy proposal.
This report was commissioned by Drug Pricing Lab.
This report was commissioned by Drug Pricing Lab.
Impact Story
01/06/2021
How a “Netflix Model” Can Help States Pay for Hepatitis C Treatment
Impact Story
11/12/2020
Testifying Before the US Senate Committee on Finance
Impact Story
11/12/2020
PR Week’s 2020 Health Influencer 50 List
News
01/31/2020
Incentives for Rare Diseases: the Right Healthcare Priorities?
Dr. Peter Bach joins Innovation Hub Radio by WGBH to discuss how incentives provided through policies have rewarded innovation for rare drugs and whether these are the right national healthcare priorities today.
Research
10/11/2019
Fact Check: Time to Market for New Drugs in U.S. Versus Other Countries
Drug prices in the U.S. are highest among developed countries, effectively setting the upper bound for reference prices elsewhere.
Research
10/11/2019
Dissecting PhRMA's Opposition to H.R. 3 Lower Drug Costs Now Act of 2019
Dr. Peter Bach responds to PhRMA's stance of opposition to H.R. 3 Lower Drug Costs Now Act of 2019.
Research
04/15/2019
Abandon Biosimilars as Biologics are Natural Monopolies
Biosimilars will not effectively lower the price of biologic drugs after the period of market exclusivity.
Research
03/08/2019
Impact of President's Budget and Point of Sale Rebate Proposal for Part D: 10 Year Projection
Milliman analyzes the impact of the proposed rule to implement point of sale rebates in Medicare Part D.
Research
03/06/2019
List Price, Net Price, and the Rebate Caught in the Middle
Pharmacy benefit managers (PBMs), such as Express Scripts, CVS Caremark, and Optum Rx, are some of the larger companies that administer the Medicare Part D prescription drug benefit.
News
01/31/2019
Dr. Bach Testifies at U.S. Senate Committee on Finance's First Hearing of Session
Dr. Peter Bach, alongside Kathy Sego, Dr. Douglas Holtz-Eakin, and Dr. Mark Miller, testified before U.S. Senate Finance Committee at its first hearing of the session, Drug Pricing in America: A Prescription for Change, Part I.
News
01/04/2019
Analysis of Medicare Part D Plans Shows $9B Upcharge
According to the Drug Pricing Lab analysis, The Wall Street Journal published an article showing $9.1 billion retained by insurers over the course of 9 years from Medicare Part D plans.
Research
08/21/2018
Cardiovascular Drugs Not Price Aligned with Value in US
U.S. prices of common cardiovascular drugs are not consistent with the cost-effectiveness evidence.
Research
06/06/2017
Copay Assistance: The Epipen Example
What happens when a patient uses a copay coupon?
Research
05/30/2017
Association of Rebates in Part D with Patient OOP and Federal Spending
The way Medicare Part D's benefit design shows that rebates actually increase patients' out-of-pocket costs while shifting spending from plan sponsors and manufacturers to Medicare.
Research
01/04/2017
Hospital Outpatient versus Doctor Office Cost for Physician Administered Cancer Drugs
A new analysis reviews several analyses of differential costs of care provided in the doctors office and hospital outpatient settings.
Research
10/10/2016
Copay Assistance for Expensive Drugs: A Helping Hand That Raises Costs
Copy assistance programs may seem to benefit public health and lower the costs of drugs, but they actually raise the costs of health care in the future.
Research
05/16/2016
Part B Pilot Congressional Concerns
Members of Congress provided conflicting forecasts on how the agency's proposed pilot program of Part B drug payment might affect aspects of Medicare beneficiary care.
News
04/05/2016
Exclusive: Makers Took Big Price Increases on Widely Used U.S. drugs
Major drug companies took hefty price increases in the U.S., in some cases more than doubling listed charges, for widely used medications over the past five years.
News
03/09/2016
Medicare Looks to Cut Drug Costs By Changing How It Pays Doctors
Medicare is going to test new ways to reimburse doctors for medications, in hopes they'll choose less expensive drugs.
News
01/12/2016
Rising Drug Costs Only Getting Worse
Drug prices have taken center stage since Turing Pharmaceuticals raised the price of its off-patent parasite-fighting drug Daraprim by over 5,000%.
No Results Found